ACROBiosystems Enhances Presence in France with The HIVE Innovation Center Hub

ACROBiosystems Expands Its Influence in France with New Hub at The HIVE

In a significant move to bolster its presence in Europe, ACROBiosystems has officially opened a dedicated hub at The HIVE Innovation Center, located within the vibrant Campus Grand Parc ecosystem in Villejuif, France. This strategic relocation marks a pivotal step for the global biotechnology company, emphasizing their commitment to solidifying ties within the region's promising life sciences community.

Founded in 2010, ACROBiosystems has established itself as a key player in the biotechnology sphere, aiming to be an essential partner for the global biopharmaceutical and healthcare sectors. With nearly 1,000 employees across Europe, North America, and Asia, the company's expansive reach supports thousands of clients, including some top-tier pharmaceutical firms, contract research organizations (CROs), and academia. The firm’s diverse product portfolio is designed to cover the entire spectrum of drug development—from recombinant proteins and antibodies to assay kits, as well as GMP-grade custom services tailored specifically for client needs.

Collaborating Within a Thriving Ecosystem

The establishment of the new hub at The HIVE Innovation Center is not merely about opening an office; it represents ACROBiosystems' intention to integrate fully into the ecosystem surrounding the Paris-Saclay region, which encompasses a mix of biotechs, hospitals, research institutes, and clinical collaborators. This collaborative atmosphere is crucial, especially in the fast-evolving field of oncology and therapeutic development.

Mike Chen, the CEO and Founder of ACROBiosystems, highlighted that France, particularly the Paris-Saclay area, is a nexus for cutting-edge scientific research and a maturing biotech community. The decision to situate their operations in this locale reflects their mission to be at the heart of innovation in oncology, immuno-oncology, advanced therapies, and other pioneering fields.

The HIVE Innovation Center stands as a melting pot for biopharmaceutical enterprises of various sizes, fostering daily interactions that are essential for collaborative growth. By embedding itself within this environment, ACROBiosystems aims to connect directly with researchers and innovators leading the charge in next-generation cancer therapies.

Commitment to Quality and Compliance

ACROBiosystems maintains a rigorous quality management system for its products, which are integral to biopharmaceutical R&D, clinical application, and companion diagnostics. Their focus on quality is seen across all stages: from targeted discovery through screening and optimization, to compliance with Good Manufacturing Practices (GMP) for clinical trials and production. The company's emphasis on reliability and integration drives their partnerships throughout the entire drug development continuum.

The opening of this office aligns with ACROBiosystems' 2025 membership in the Paris-Saclay Cancer Cluster (PSCC), further entrenching their ties to the local scientific community. Through this cluster, researchers gain access to invaluable resources, including funding opportunities, laboratory access, and mentorship, essential for advancing cancer research and innovation in the European context.

A Growing Attraction of the Ecosystem

Kadans Science Partner, the real estate entity behind The HIVE, views ACROBiosystems' investment as a vote of confidence in the local ecosystem's global appeal. Sandrine Lo, the Investment & Asset Manager of Kadans Science Partner, remarked on the establishment of ACROBiosystems in the Campus Grand Parc, asserting it as indicative of the area's increasing attractiveness to international businesses.

With their new facility at The HIVE, ACROBiosystems signals a commitment not only to growing as a proactive technology leader but also to actively engage in the collaborative and innovative environment that the Paris-Saclay region promises. The integration of their services with local actors positions them uniquely to contribute to advancements in healthcare and drug development worldwide.

Conclusion

ACROBiosystems' expansion into France serves as a testament to both the company's growth trajectory and the allure of the European biotech landscape. As they set up their new hub at The HIVE Innovation Center, they are not just opening new doors; they are forging lasting connections that will aim to revolutionize oncology and therapeutic landscapes in the years to come.